<?xml version="1.0" encoding="UTF-8"?><measure><measureDetails><uuid>40280381-3e93-d1af-013e-9e3e037e08d6</uuid><title>ADE Prevention and Monitoring: Warfarin Time in Therapeutic Range</title><shortTitle>ADE TTR CVM</shortTitle><emeasureid>179</emeasureid><guid>a5e96a45-8132-4e72-bf4f-e8c81db9e641</guid><version>3</version><status>In Progress</status><nqfid extension="NA" root="2.16.840.1.113883.3.560.1"/><period uuid="fc82b0e5-65e0-4b10-aa25-137c89f94c5c"><startDate uuid="0ad0bd59-f96c-42d4-a460-37188abf9cc1">00000101</startDate><stopDate uuid="d051cbc7-baa4-4cf1-94e8-0190c5824670">00001231</stopDate></period><steward id="2.16.840.1.113883.3.560.3.31">Centers for Medicare &amp; Medicaid Services</steward><developers><developer id="2.16.840.1.113883.3.464">National Committee for Quality Assurance</developer></developers><description>Average percentage of time in which patients aged 18 and older with atrial fibrillation who are on chronic warfarin therapy have International Normalized Ratio (INR) test results within the therapeutic range (i.e., TTR) during the measurement period.</description><copyright>Limited proprietary coding is contained in the Measure specifications for user convenience. Users of proprietary code sets should obtain all necessary licenses from the owners of the code sets.  &#xD;
&#xD;
CPT(R) contained in the Measure specifications is copyright 2004-2012 American Medical Association. LOINC(R) copyright 2004-2012 Regenstrief Institute, Inc. This material contains SNOMED Clinical Terms(R) (SNOMED CT[R]) copyright 2004-2012 International Health Terminology Standards Development Organisation. ICD-10 copyright 2012 World Health Organization. All Rights Reserved.</copyright><disclaimer>These performance Measures are not clinical guidelines and do not establish a standard of medical care, and have not been tested for all potential applications.&#xD;
&#xD;
THE MEASURES AND SPECIFICATIONS ARE PROVIDED ?AS IS? WITHOUT WARRANTY OF ANY KIND.&#xD;
&#xD;
Due to technical limitations, registered trademarks are indicated by (R) or [R] and unregistered trademarks are indicated by (TM) or [TM].</disclaimer><scoring id="CONTVAR">Continuous Variable</scoring><types><type id="OUTCOME">Outcome</type></types><stratification>None</stratification><riskAdjustment>TBD</riskAdjustment><aggregation>None</aggregation><rationale>Millions of patients in the United States use warfarin to prevent strokes or to prevent or treat venous thromboembolism. Warfarin is highly effective, and has been in clinical use for over 50 years (Rose 2009a). However, warfarin is difficult to manage because it has many possible interactions with diet, other drugs, and comorbid conditions that may destabilize anticoagulation control (Rose 2009b). The possible consequences of insufficient or excessive anticoagulation are extremely serious and often fatal, making it imperative to pursue good control (White 2007).&#xD;
&#xD;
The international normalized ratio (INR) test is the laboratory test used to determine the degree to which the patient's coagulation has been successfully suppressed by the vitamin K antagonist (VKA). For most patients, the goal is to keep the INR between 2 and 3, which roughly corresponds to the blood taking 2 to 3 times as long to clot as would a normal person's blood. This level of anticoagulation has been shown to maximize benefit (i.e., protect patients from blood clots) while minimizing risk (i.e., risk of hemorrhage attributable to excessive anticoagulation) (Holbrook 2012). Time in therapeutic INR range (TTR) is a way of summarizing INR control over time (Phillips 2008).&#xD;
&#xD;
TTR has been followed before, mostly in the setting of clinical trials where it is used to evaluate the effectiveness of warfarin therapy, particularly when warfarin is being compared to some other strategy. However, TTR has not previously been used as a quality measure ? in fact, there has been a general lack of quality measurement in oral anticoagulation. There is much evidence that better anticoagulation control (i.e., higher TTR) can protect patients from severe or even fatal adverse events (Phillips 2008, Connolly 2008).&#xD;
&#xD;
The 2012 ACCP anticoagulation clinical practice guidelines recommend a routine INR testing frequency of up to 12 weeks for patients on stable warfarin dosing (Holbrook 2012).  Therefore, all patients who are on chronic warfarin should have at least 4 INR tests during a 12-month period or at least 1 INR test during each 12-week period of a measurement year. Any patient in this population that does not either have at least one INR test result in each 12-week period OR a valid reason for not having an INR test performed in that time period is not undergoing minimum appropriate monitoring.&#xD;
&#xD;
This quality measure is not intended to differentiate between stable versus unstable warfarin dosing for the following reasons. There is no prevailing definition of ?stable? warfarin dosing and a valid, reliable method for determining the status of patients? warfarin dosing is not available. In 2012, the ACCP anticoagulation guidelines suggest a definition for stable ? defined as ?at least 3 months of consistent results with no need to adjust VKA dosing? (Holbrook 2012). Because the measurement period is set to only one year, it would be impossible to fully implement criteria for identifying patients whose dose has not changed in 3 months.  Also, because dose information is not consistently found in EHRs, building measure logic that is dependent on the availability of dose and dose adjustments was determined to not be currently feasible by a panel of subject matter experts. &#xD;
&#xD;
Because the target therapeutic range for patients with atrial flutter is the same as that for atrial fibrillation without valvular heart disease (Guyatt 2012), patients with atrial flutter are also included in the denominator of this measure.</rationale><recommendations>?For patients with AF, including those with paroxysmal AF, who are at low risk of stroke (eg, CHADS 2 [congestive heart failure, hypertension, age 75 years, diabetes mellitus, prior stroke or transient ischemic attack] score = 0), we suggest no therapy rather than antithrombotic therapy (Grade 2B) . For patients who do choose antithrombotic therapy, we suggest aspirin (75 mg to 325 mg once daily) rather than oral anticoagulation (Grade 2B) or combination therapy with aspirin and clopidogrel (Grade 2B).? (Guyatt 2012)&#xD;
&#xD;
?For patients with AF, including those with paroxysmal AF, who are at intermediate risk of stroke (eg, CHADS 2 score = 1), we recommend oral anticoagulation rather than no therapy (Grade 1B). We suggest oral anticoagulation rather than aspirin (75 mg to 325 mg once daily) (Grade 2B) or combination therapy with aspirin and clopidogrel (Grade 2B). For patients who are unsuitable for or choose not to take an oral anticoagulant (for reasons other than concerns about major bleeding), we suggest combination therapy with aspirin and clopidogrel rather than aspirin (75 mg to 325 mg once daily) (Grade 2B).? (Guyatt 2012)&#xD;
&#xD;
?For patients with AF, including those with paroxysmal AF, who are at high risk of stroke (eg, CHADS 2 score = 2), we recommend oral anticoagulation rather than no therapy (Grade 1A), aspirin (75 mg to 325 mg once daily) (Grade 1B), or combination therapy with aspirin and clopidogrel (Grade 1B). For patients who are unsuitable for or choose not to take an oral anticoagulant (for reasons other than concerns about major bleeding), we recommend combination therapy with aspirin and clopidogrel rather than aspirin (75 mg to 325 mg once daily) (Grade 1B).? (Guyatt 2012)&#xD;
&#xD;
?For patients with AF, including those with paroxysmal AF, for recommendations in favor of oral anticoagulation (including 2.1.9, 2.1.10, and excluding 2.2, 3.1, 3.2, 3.3), we suggest dabigatran 150 mg twice daily rather than adjusted-dose VKA therapy (target INR range, 2.0-3.0) (Grade 2B).? (Guyatt 2012)&#xD;
&#xD;
 ?For patients taking VKA therapy with consistently stable INRs, we suggest INR testing frequency of up to 12 weeks rather than every 4 weeks (Grade 2B).? (Holbrook 2012)</recommendations><improvementNotations>A higher score indicates higher quality</improvementNotations><references><reference>Connolly SJ, Pogue J, Eikelboom J, Flaker G, Commerford P, Franzosi MG, Healey JS, Yusuf S, ACTIVE W Investigators. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008 Nov 11;118(20):2029-37. [21 references] PubMed</reference><reference>Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schunemann HJ. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (9th Edition). Chest. 2012; 141(2): 7S-47S.</reference><reference>Holbrook A, Schulman S, Witt DM, Vandvik PO, Fish J, Kovacs MJ, Svensson PJ, Veenstra DL, Crowther M, Guyatt GH. Evidence-Based Management of Anticoagulant Therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e152S-e84S.</reference><reference>Phillips KW, Ansell J. Outpatient management of oral vitamin K antagonist therapy: defining and measuring high-quality measurement. Expert Rev Cardiovasc Ther 2008 6(1); 57-70.</reference><reference>Rose AJ, Berlowitz DR, Frayne SM, Hylek EM. Measuring quality of oral anticoagulation care: extending quality measurement to a new field. Jt Comm J Qual Patient Saf 2009a; 35(3):146-55. </reference><reference>Rose AJ, Ozonoff A, Berlowitz DR, Henault LE, Hylek EM. Warfarin dose management affects INR control. J Thromb Haemost&#xD;
2009b; 7: 94?101.&#xD;
</reference><reference>Rose A. Staff physician, Bedford VA Medical Center. Investigator, VA Center for Health Quality, Outcomes, and Economic Research at the Bedford VA. Assistant Professor, Boston University School of Medicine. Percent time in therapeutic INR range (TTR). 2010 Oct 7. 8 p.</reference><reference>White HD, Gruber M, Feyzi J, Kaatz S, Tse HF, Husted S, Albers GW. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med 2007; 167(3):239-45.</reference></references><definitions>CUMULATIVE MEDICATION DURATION is the total number of calendar days that an individual has active medications that contain the same drug ingredient of interest. In this measure, the active drug ingredient is warfarin. The number of active days of an occurrence of a medication (e.g., a medication order or an entry in a patient's medication list) is calculated by taking the difference (in calendar days) between the date that the medication became active and the date that the medication stopped being active. The cumulative medication duration is calculated as the sum of the number of active calendar days for each occurrence of a medication that contains the same active ingredient over a set period of time, excluding any gaps during which a medication was not active. All of the entries in the value set for warfarin (OID: 2.16.840.1.113883.3.117.1.7.1.232) must be included in determining the cumulative medication duration. All medication occurrences considered for the calculation of cumulative medication duration for this measure must be active within 200 days immediately prior to the measurement period. This lookback period of 200 days is based on the original warfarin TTR measure used by the Veterans Affairs health care system. Please refer to the supplemental file named ?CMS179v2_Supplemental_SQL_Logic_Reference.pdf? for this logic.&#xD;
&#xD;
A VALID INR INTERVAL is two INR values separated by 56 days or less. INR values must be obtained in outpatient care settings; INR values while the patient is admitted to a hospital for more than 23 hours should not be included.&#xD;
&#xD;
THERAPEUTIC RANGE: for patients with atrial fibrillation and no valvular involvement, the target INR result = 2.0 ? 3.0.&#xD;
&#xD;
PERCENT OF TIME IN THERAPEUTIC RANGE (TTR) is the percentage of time during which the INR values lie between 2.0 and 3.0. This can be from 0% to 100%. TTR percentage should be calculated for each patient that meets the criteria for the Measure Population. The average of these values is reported as the Measure Observation. &#xD;
&#xD;
There are two ways in which a TTR can be calculated for each patient. For patients with minimum appropriate monitoring who have all of their INR values within therapeutic range, their TTR by definition is 100%. No further calculation to determine TTR is necessary for these patients. For patients with minimum appropriate monitoring who have at least 1 INR that is not therapeutic, then we check whether or not the patient has sufficient INR results to calculate a TTR using interpolation of INR values (aka Rosendaal method). The instructions to perform this calculation are included in in the supplemental file named ?CMS179v2_Supplemental_SQL_Logic_Reference.pdf?. Patients that do not have sufficient INR results to calculate TTR using the Rosendaal method are removed from the Measure Population. The TTRs from both calculation methods are combined in order to calculate the Measure Observation.&#xD;
&#xD;
INTERPOLATED INR VALUES are obtained through the use of linear interpolation to assign an INR value to each day between successive observed INR values. The Rosendaal linear interpolation methodology used in this measure assumes a linear relationship between two INR values and allows the assignment of a specific INR to each day for each patient.</definitions><guidance>Please note that the logic expressions in the body section of the HQMF of this measure should not be used to calculate the TTR needed for the clinical quality measure. In order to calculate this clinical quality measure and a TTR for each patient, use the annotated database query found in the supplemental file named ?CMS179v2_Supplemental_SQL_Logic_Reference.pdf?.&#xD;
&#xD;
The calculation of TTR should include all available INR values for a given patient during the measurement period. When generating a QRDA-1 document for this measure, all available INR values during the measurement period should be included.&#xD;
&#xD;
The following filters are applied to each patient?s INRs in order to calculate a patient-level TTR. INR values must be at least 0.8. Values less than 0.8 may represent aberrant results. INR values greater than 10 (i.e., outliers) must be replaced with a value of 10. An INR of 10 represents an abnormally high INR and would skew the results of the calculated TTR less than extreme values would (i.e., INR &gt; 10). The INR value closest to "2.5" is used to calculate TTR, when there are more than one INR result on a single date.&#xD;
&#xD;
In this measure, the active drug ingredient of primary interest is warfarin. CUMULATIVE MEDICATION DURATION should be calculated for all active warfarin-containing medications. All of the entries in the value set for warfarin must be included when determining the cumulative medication duration. All medication occurrences considered for the calculation of cumulative medication duration for this measure must be active within 200 days immediately prior to the measurement period. This lookback period of 200 days is based on the original warfarin TTR measure used by the Veterans Affairs health care system. Please refer to the supplemental file named ?CMS179v2 _Supplemental_SQL_Logic_Reference.pdf? for this logic.&#xD;
&#xD;
The 12 month measurement period is divided into four, consecutive, non-overlapping 90 day periods. A 90-day period is used because it approximates the maximum 12-week INR monitoring interval specified in the 2012 ACCP anticoagulation clinical practice guidelines. Each patient on chronic warfarin therapy is expected to have at least one INR during every 90-day period, unless the patient is on either dabigatran or rivaroxaban. This eMeasure has logic that assesses whether or not a patient is on one of these two medications during 1 or more 90-day periods during a measurement period.&#xD;
&#xD;
To determine the proportion of patients with atrial fibrillation who are on chronic warfarin therapy and have sufficient INR monitoring to calculate a TTR, the reporting provider can divide the Measure Population by the Initial Patient Population.&#xD;
&#xD;
The Measure Observation is the average of all patients? percent TTR, which can be calculated by dividing the sum of all patients? percent TTR by the number of patients in the Measure Population.</guidance><transmissionFormat>None</transmissionFormat><initialPatientPopDescription>Patients aged 18 and older with atrial fibrillation without valvular heart disease who had been on chronic warfarin therapy for at least 180 days before the start of the measurement period. Patient should have at least one outpatient visit during the measurement period</initialPatientPopDescription><denominatorDescription>Not Applicable</denominatorDescription><denominatorExclusionsDescription>Not Applicable</denominatorExclusionsDescription><numeratorDescription>Not Applicable</numeratorDescription><numeratorExclusionsDescription>Not Applicable</numeratorExclusionsDescription><denominatorExceptionsDescription>Not Applicable</denominatorExceptionsDescription><measurePopulationDescription>Equals All in Initial Patient Population with sufficient international normalized ratio (INR) results to calculate a warfarin time in therapeutic range (TTR)</measurePopulationDescription><measureObservationsDescription>Average percentage of time that patients in the measure population have INR results within the therapeutic range (i.e., TTR)</measureObservationsDescription><supplementalData>For every patient evaluated by this measure also identify payer, race, ethnicity and sex.</supplementalData><qualityMeasureSet uuid="49778749-afd3-4628-a250-2c738b2a07b7">None</qualityMeasureSet>
<finalizedDate value="201308180036-0500"/>
</measureDetails><supplementalDataElements><elementRef id="40280381-3e93-d1af-013e-9e3e039a08d7" name="ONC Administrative Sex"/><elementRef id="40280381-3e93-d1af-013e-9e3e039a08d8" name="Race"/><elementRef id="40280381-3e93-d1af-013e-9e3e039a08d9" name="Ethnicity"/><elementRef id="40280381-3e93-d1af-013e-9e3e039a08da" name="Payer"/></supplementalDataElements><measureGrouping><group sequence="1"><clause displayName="Initial Patient Population 1" type="initialPatientPopulation" uuid="6C6ACEB5-959B-4553-B19F-96A7971049EB"><logicalOp displayName="AND" type="and"><relationalOp displayName="&gt;= 18 years Starts Before Start Of" operatorType="Greater Than or Equal To" quantity="18" type="SBS" unit="years"><elementRef displayName="birth date : Patient Characteristic Birthdate" id="40280381-3e93-d1af-013e-9e3e039b08e2" type="qdm"/><elementRef displayName="Measurement Period : Timing Element" id="40280381-3e93-d1af-013e-9e3e039b08e7" type="qdm"/></relationalOp><relationalOp displayName="During" type="DURING"><logicalOp displayName="OR" type="or"><elementRef displayName="Face-to-Face Interaction : Encounter, Performed" id="40280381-3e93-d1af-013e-9e3e039b08ec" type="qdm"/><elementRef displayName="Office Visit : Encounter, Performed" id="40280381-3e93-d1af-013e-9e3e039a08e0" type="qdm"/></logicalOp><elementRef displayName="Measurement Period : Timing Element" id="40280381-3e93-d1af-013e-9e3e039b08e7" type="qdm"/></relationalOp><logicalOp displayName="AND" type="and"><relationalOp displayName="Starts Before Start Of" type="SBS"><elementRef displayName="Occurrence A of Atrial Fibrillation/Flutter : Diagnosis, Active" id="40280381-3e93-d1af-013e-9e3e039b08ed" type="qdm"/><elementRef displayName="Measurement Period : Timing Element" id="40280381-3e93-d1af-013e-9e3e039b08e7" type="qdm"/></relationalOp><functionalOp displayName="NOT" type="NOT" uuid="03cccd29-4a89-414b-b692-4ac22cabc921"><relationalOp displayName="Ends Before Start Of" type="EBS"><elementRef displayName="Occurrence A of Atrial Fibrillation/Flutter : Diagnosis, Active" id="40280381-3e93-d1af-013e-9e3e039b08ed" type="qdm"/><elementRef displayName="Measurement Period : Timing Element" id="40280381-3e93-d1af-013e-9e3e039b08e7" type="qdm"/></relationalOp></functionalOp></logicalOp><logicalOp displayName="OR" type="or"><functionalOp displayName="NOT" type="NOT" uuid="760522eb-665e-4d23-bb2b-3ee068bbb1c6"><relationalOp displayName="Starts Before Or During" type="SBOD"><elementRef displayName="Occurrence A of Valvular Heart Disease : Diagnosis, Active" id="40280381-3e93-d1af-013e-9e3e039b08ee" type="qdm"/><elementRef displayName="Measurement Period : Timing Element" id="40280381-3e93-d1af-013e-9e3e039b08e7" type="qdm"/></relationalOp></functionalOp><relationalOp displayName="Ends Before Start Of" type="EBS"><elementRef displayName="Occurrence A of Valvular Heart Disease : Diagnosis, Active" id="40280381-3e93-d1af-013e-9e3e039b08ee" type="qdm"/><elementRef displayName="Measurement Period : Timing Element" id="40280381-3e93-d1af-013e-9e3e039b08e7" type="qdm"/></relationalOp></logicalOp><logicalOp displayName="AND" type="and"><relationalOp displayName="&lt;= 200 days Starts Before Start Of" operatorType="Less Than or Equal To" quantity="200" type="SBS" unit="days"><elementRef displayName="Warfarin : Medication, Active" id="40280381-3e93-d1af-013e-9e3e039b08ef" type="qdm"><attribute comparisonValue="180" mode="Greater Than or Equal To" name="cumulative medication duration" unit="days"/></elementRef><elementRef displayName="Measurement Period : Timing Element" id="40280381-3e93-d1af-013e-9e3e039b08e7" type="qdm"/></relationalOp><logicalOp displayName="AND" type="and"><relationalOp displayName="Starts Before Or During" type="SBOD"><elementRef displayName="Occurrence A of Warfarin : Medication, Active" id="40280381-3e93-d1af-013e-9e3e039b08f0" type="qdm"/><elementRef displayName="Measurement Period : Timing Element" id="40280381-3e93-d1af-013e-9e3e039b08e7" type="qdm"/></relationalOp><functionalOp displayName="NOT" type="NOT" uuid="3d41af48-e103-4fc9-b768-58c343beac94"><relationalOp displayName="Ends Before Start Of" type="EBS"><elementRef displayName="Occurrence A of Warfarin : Medication, Active" id="40280381-3e93-d1af-013e-9e3e039b08f0" type="qdm"/><elementRef displayName="Measurement Period : Timing Element" id="40280381-3e93-d1af-013e-9e3e039b08e7" type="qdm"/></relationalOp></functionalOp></logicalOp></logicalOp><logicalOp displayName="AND" type="and"><logicalOp displayName="OR" type="or"><logicalOp displayName="AND" type="and"><relationalOp displayName="Starts After Start Of" type="SAS"><elementRef displayName="Occurrence A of INR : Laboratory Test, Result" id="40280381-3e93-d1af-013e-9e3e039b08e8" type="qdm"/><elementRef displayName="Measurement Period : Timing Element" id="40280381-3e93-d1af-013e-9e3e039b08e7" type="qdm"/></relationalOp><relationalOp displayName="&lt;= 91 days Starts After Start Of" operatorType="Less Than or Equal To" quantity="91" type="SAS" unit="days"><elementRef displayName="Occurrence A of INR : Laboratory Test, Result" id="40280381-3e93-d1af-013e-9e3e039b08e8" type="qdm"/><elementRef displayName="Measurement Period : Timing Element" id="40280381-3e93-d1af-013e-9e3e039b08e7" type="qdm"/></relationalOp></logicalOp><logicalOp displayName="AND" type="and"><functionalOp displayName="NOT" type="NOT" uuid="c042be17-83d9-4272-adfa-b0fb33b76449"><relationalOp displayName="&gt;= 92 days Starts After Start Of" operatorType="Greater Than or Equal To" quantity="92" type="SAS" unit="days"><logicalOp displayName="OR" type="or"><elementRef displayName="Dabigatran : Medication, Active" id="40280381-3e93-d1af-013e-fb53b9f4456b" type="qdm"/><elementRef displayName="Rivaroxaban : Medication, Active" id="40280381-3e93-d1af-013e-fb53b9f5456c" type="qdm"/></logicalOp><elementRef displayName="Measurement Period : Timing Element" id="40280381-3e93-d1af-013e-9e3e039b08e7" type="qdm"/></relationalOp></functionalOp><relationalOp displayName="During" type="DURING"><logicalOp displayName="OR" type="or"><elementRef displayName="Dabigatran : Medication, Active" id="40280381-3e93-d1af-013e-fb53b9f4456b" type="qdm"/><elementRef displayName="Rivaroxaban : Medication, Active" id="40280381-3e93-d1af-013e-fb53b9f5456c" type="qdm"/></logicalOp><elementRef displayName="Measurement Period : Timing Element" id="40280381-3e93-d1af-013e-9e3e039b08e7" type="qdm"/></relationalOp></logicalOp></logicalOp><logicalOp displayName="OR" type="or"><logicalOp displayName="AND" type="and"><relationalOp displayName="&gt;= 92 days Starts After Start Of" operatorType="Greater Than or Equal To" quantity="92" type="SAS" unit="days"><elementRef displayName="Occurrence B of INR : Laboratory Test, Result" id="40280381-3e93-d1af-013e-9e3e039b08e9" type="qdm"/><elementRef displayName="Measurement Period : Timing Element" id="40280381-3e93-d1af-013e-9e3e039b08e7" type="qdm"/></relationalOp><relationalOp displayName="&lt;= 182 days Starts After Start Of" operatorType="Less Than or Equal To" quantity="182" type="SAS" unit="days"><elementRef displayName="Occurrence B of INR : Laboratory Test, Result" id="40280381-3e93-d1af-013e-9e3e039b08e9" type="qdm"/><elementRef displayName="Measurement Period : Timing Element" id="40280381-3e93-d1af-013e-9e3e039b08e7" type="qdm"/></relationalOp></logicalOp><logicalOp displayName="AND" type="and"><relationalOp displayName="During" type="DURING"><logicalOp displayName="OR" type="or"><elementRef displayName="Dabigatran : Medication, Active" id="40280381-3e93-d1af-013e-fb53b9f4456b" type="qdm"/><elementRef displayName="Rivaroxaban : Medication, Active" id="40280381-3e93-d1af-013e-fb53b9f5456c" type="qdm"/></logicalOp><elementRef displayName="Measurement Period : Timing Element" id="40280381-3e93-d1af-013e-9e3e039b08e7" type="qdm"/></relationalOp><functionalOp displayName="NOT" type="NOT" uuid="6d170ea2-b1d1-48bd-92e9-ed9d9d32c64a"><relationalOp displayName="&lt;= 91 days Ends After Start Of" operatorType="Less Than or Equal To" quantity="91" type="EAS" unit="days"><logicalOp displayName="OR" type="or"><elementRef displayName="Dabigatran : Medication, Active" id="40280381-3e93-d1af-013e-fb53b9f4456b" type="qdm"/><elementRef displayName="Rivaroxaban : Medication, Active" id="40280381-3e93-d1af-013e-fb53b9f5456c" type="qdm"/></logicalOp><elementRef displayName="Measurement Period : Timing Element" id="40280381-3e93-d1af-013e-9e3e039b08e7" type="qdm"/></relationalOp></functionalOp><functionalOp displayName="NOT" type="NOT" uuid="8fcc5515-0739-48f3-b46f-2c26b0d7af83"><relationalOp displayName="&gt;= 183 days Starts After Start Of" operatorType="Greater Than or Equal To" quantity="183" type="SAS" unit="days"><logicalOp displayName="OR" type="or"><elementRef displayName="Dabigatran : Medication, Active" id="40280381-3e93-d1af-013e-fb53b9f4456b" type="qdm"/><elementRef displayName="Rivaroxaban : Medication, Active" id="40280381-3e93-d1af-013e-fb53b9f5456c" type="qdm"/></logicalOp><elementRef displayName="Measurement Period : Timing Element" id="40280381-3e93-d1af-013e-9e3e039b08e7" type="qdm"/></relationalOp></functionalOp></logicalOp></logicalOp><logicalOp displayName="OR" type="or"><logicalOp displayName="AND" type="and"><relationalOp displayName="&gt;= 183 days Starts After Start Of" operatorType="Greater Than or Equal To" quantity="183" type="SAS" unit="days"><elementRef displayName="Occurrence C of INR : Laboratory Test, Result" id="40280381-3e93-d1af-013e-9e3e039b08ea" type="qdm"/><elementRef displayName="Measurement Period : Timing Element" id="40280381-3e93-d1af-013e-9e3e039b08e7" type="qdm"/></relationalOp><relationalOp displayName="&lt;= 273 days Starts After Start Of" operatorType="Less Than or Equal To" quantity="273" type="SAS" unit="days"><elementRef displayName="Occurrence C of INR : Laboratory Test, Result" id="40280381-3e93-d1af-013e-9e3e039b08ea" type="qdm"/><elementRef displayName="Measurement Period : Timing Element" id="40280381-3e93-d1af-013e-9e3e039b08e7" type="qdm"/></relationalOp></logicalOp><logicalOp displayName="AND" type="and"><relationalOp displayName="During" type="DURING"><logicalOp displayName="OR" type="or"><elementRef displayName="Dabigatran : Medication, Active" id="40280381-3e93-d1af-013e-fb53b9f4456b" type="qdm"/><elementRef displayName="Rivaroxaban : Medication, Active" id="40280381-3e93-d1af-013e-fb53b9f5456c" type="qdm"/></logicalOp><elementRef displayName="Measurement Period : Timing Element" id="40280381-3e93-d1af-013e-9e3e039b08e7" type="qdm"/></relationalOp><functionalOp displayName="NOT" type="NOT" uuid="5ce1dc1d-ca00-4f8d-a651-f448b5d89a28"><relationalOp displayName="&lt;= 182 days Ends After Start Of" operatorType="Less Than or Equal To" quantity="182" type="EAS" unit="days"><logicalOp displayName="OR" type="or"><elementRef displayName="Dabigatran : Medication, Active" id="40280381-3e93-d1af-013e-fb53b9f4456b" type="qdm"/><elementRef displayName="Rivaroxaban : Medication, Active" id="40280381-3e93-d1af-013e-fb53b9f5456c" type="qdm"/></logicalOp><elementRef displayName="Measurement Period : Timing Element" id="40280381-3e93-d1af-013e-9e3e039b08e7" type="qdm"/></relationalOp></functionalOp><functionalOp displayName="NOT" type="NOT" uuid="eea1352f-1d16-4f16-bb1f-3c45970fa3a2"><relationalOp displayName="&gt;= 274 days Starts After Start Of" operatorType="Greater Than or Equal To" quantity="274" type="SAS" unit="days"><logicalOp displayName="OR" type="or"><elementRef displayName="Dabigatran : Medication, Active" id="40280381-3e93-d1af-013e-fb53b9f4456b" type="qdm"/><elementRef displayName="Rivaroxaban : Medication, Active" id="40280381-3e93-d1af-013e-fb53b9f5456c" type="qdm"/></logicalOp><elementRef displayName="Measurement Period : Timing Element" id="40280381-3e93-d1af-013e-9e3e039b08e7" type="qdm"/></relationalOp></functionalOp></logicalOp></logicalOp><logicalOp displayName="OR" type="or"><logicalOp displayName="AND" type="and"><relationalOp displayName="&gt;= 274 days Starts After Start Of" operatorType="Greater Than or Equal To" quantity="274" type="SAS" unit="days"><elementRef displayName="Occurrence D of INR : Laboratory Test, Result" id="40280381-3e93-d1af-013e-9e3e039b08eb" type="qdm"/><elementRef displayName="Measurement Period : Timing Element" id="40280381-3e93-d1af-013e-9e3e039b08e7" type="qdm"/></relationalOp><relationalOp displayName="&lt;= 365 days Starts After Start Of" operatorType="Less Than or Equal To" quantity="365" type="SAS" unit="days"><elementRef displayName="Occurrence D of INR : Laboratory Test, Result" id="40280381-3e93-d1af-013e-9e3e039b08eb" type="qdm"/><elementRef displayName="Measurement Period : Timing Element" id="40280381-3e93-d1af-013e-9e3e039b08e7" type="qdm"/></relationalOp></logicalOp><logicalOp displayName="AND" type="and"><relationalOp displayName="During" type="DURING"><logicalOp displayName="OR" type="or"><elementRef displayName="Dabigatran : Medication, Active" id="40280381-3e93-d1af-013e-fb53b9f4456b" type="qdm"/><elementRef displayName="Rivaroxaban : Medication, Active" id="40280381-3e93-d1af-013e-fb53b9f5456c" type="qdm"/></logicalOp><elementRef displayName="Measurement Period : Timing Element" id="40280381-3e93-d1af-013e-9e3e039b08e7" type="qdm"/></relationalOp><functionalOp displayName="NOT" type="NOT" uuid="0bbc887c-d718-430b-9a47-ea2fd7a28791"><relationalOp displayName="&lt;= 273 days Ends After Start Of" operatorType="Less Than or Equal To" quantity="273" type="EAS" unit="days"><logicalOp displayName="OR" type="or"><elementRef displayName="Dabigatran : Medication, Active" id="40280381-3e93-d1af-013e-fb53b9f4456b" type="qdm"/><elementRef displayName="Rivaroxaban : Medication, Active" id="40280381-3e93-d1af-013e-fb53b9f5456c" type="qdm"/></logicalOp><elementRef displayName="Measurement Period : Timing Element" id="40280381-3e93-d1af-013e-9e3e039b08e7" type="qdm"/></relationalOp></functionalOp></logicalOp></logicalOp></logicalOp></logicalOp></clause><clause displayName="Measure Population 1" type="measurePopulation" uuid="AB838720-80E1-4B4C-AC2B-01290CE0FBD6"><logicalOp displayName="AND" type="and"/></clause></group></measureGrouping><elementLookUp><qdm codeSystemName="National Library of Medicine" datatype="Patient Characteristic Sex" id="40280381-3e93-d1af-013e-9e3e039a08d7" name="ONC Administrative Sex" oid="2.16.840.1.113762.1.4.1" suppDataElement="true" taxonomy="Administrative Sex" uuid="40280381-3e93-d1af-013e-9e3e039a08d7" version="1"/><qdm codeSystemName="CDC NCHS" datatype="Patient Characteristic Race" id="40280381-3e93-d1af-013e-9e3e039a08d8" name="Race" oid="2.16.840.1.114222.4.11.836" suppDataElement="true" taxonomy="CDC" uuid="40280381-3e93-d1af-013e-9e3e039a08d8" version="1"/><qdm codeSystemName="CDC NCHS" datatype="Patient Characteristic Ethnicity" id="40280381-3e93-d1af-013e-9e3e039a08d9" name="Ethnicity" oid="2.16.840.1.114222.4.11.837" suppDataElement="true" taxonomy="CDC" uuid="40280381-3e93-d1af-013e-9e3e039a08d9" version="1"/><qdm codeSystemName="PHDSC" datatype="Patient Characteristic Payer" id="40280381-3e93-d1af-013e-9e3e039a08da" name="Payer" oid="2.16.840.1.114222.4.11.3591" suppDataElement="true" taxonomy="Source of Payment Typology" uuid="40280381-3e93-d1af-013e-9e3e039a08da" version="1"/><qdm codeSystemName="National Committee for Quality Assurance" datatype="Encounter, Performed" id="40280381-3e93-d1af-013e-9e3e039a08e0" name="Office Visit" oid="2.16.840.1.113883.3.464.1003.101.12.1001" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3e93-d1af-013e-9e3e039a08e0" version="1"/><qdm codeSystemName="National Quality Forum" datatype="Patient Characteristic Birthdate" id="40280381-3e93-d1af-013e-9e3e039b08e2" name="birth date" oid="2.16.840.1.113883.3.560.100.4" suppDataElement="false" taxonomy="LOINC" uuid="40280381-3e93-d1af-013e-9e3e039b08e2" version="1"/><qdm codeSystemName="National Quality Forum" datatype="Timing Element" id="40280381-3e93-d1af-013e-9e3e039b08e7" name="Measurement Period" oid="2.16.840.1.113883.3.67.1.101.1.53" suppDataElement="false" taxonomy="NQF" uuid="40280381-3e93-d1af-013e-9e3e039b08e7" version="1"/><qdm codeSystemName="Joint Commission" datatype="Laboratory Test, Result" id="40280381-3e93-d1af-013e-9e3e039b08e8" instance="Occurrence A" name="INR" oid="2.16.840.1.113883.3.117.1.7.1.213" suppDataElement="false" taxonomy="LOINC" uuid="40280381-3e93-d1af-013e-9e3e039b08e8" version="1"/><qdm codeSystemName="Joint Commission" datatype="Laboratory Test, Result" id="40280381-3e93-d1af-013e-9e3e039b08e9" instance="Occurrence B" name="INR" oid="2.16.840.1.113883.3.117.1.7.1.213" suppDataElement="false" taxonomy="LOINC" uuid="40280381-3e93-d1af-013e-9e3e039b08e9" version="1"/><qdm codeSystemName="Joint Commission" datatype="Laboratory Test, Result" id="40280381-3e93-d1af-013e-9e3e039b08ea" instance="Occurrence C" name="INR" oid="2.16.840.1.113883.3.117.1.7.1.213" suppDataElement="false" taxonomy="LOINC" uuid="40280381-3e93-d1af-013e-9e3e039b08ea" version="1"/><qdm codeSystemName="Joint Commission" datatype="Laboratory Test, Result" id="40280381-3e93-d1af-013e-9e3e039b08eb" instance="Occurrence D" name="INR" oid="2.16.840.1.113883.3.117.1.7.1.213" suppDataElement="false" taxonomy="LOINC" uuid="40280381-3e93-d1af-013e-9e3e039b08eb" version="1"/><qdm codeSystemName="National Committee for Quality Assurance" datatype="Encounter, Performed" id="40280381-3e93-d1af-013e-9e3e039b08ec" name="Face-to-Face Interaction" oid="2.16.840.1.113883.3.464.1003.101.12.1048" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3e93-d1af-013e-9e3e039b08ec" version="1"/><qdm codeSystemName="Joint Commission" datatype="Diagnosis, Active" id="40280381-3e93-d1af-013e-9e3e039b08ed" instance="Occurrence A" name="Atrial Fibrillation/Flutter" oid="2.16.840.1.113883.3.117.1.7.1.202" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3e93-d1af-013e-9e3e039b08ed" version="1"/><qdm codeSystemName="National Committee for Quality Assurance" datatype="Diagnosis, Active" id="40280381-3e93-d1af-013e-9e3e039b08ee" instance="Occurrence A" name="Valvular Heart Disease" oid="2.16.840.1.113883.3.464.1003.104.12.1017" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3e93-d1af-013e-9e3e039b08ee" version="1"/><qdm codeSystemName="Joint Commission" datatype="Medication, Active" id="40280381-3e93-d1af-013e-9e3e039b08ef" name="Warfarin" oid="2.16.840.1.113883.3.117.1.7.1.232" suppDataElement="false" taxonomy="RxNorm" uuid="40280381-3e93-d1af-013e-9e3e039b08ef" version="1"/><qdm codeSystemName="Joint Commission" datatype="Medication, Active" id="40280381-3e93-d1af-013e-9e3e039b08f0" instance="Occurrence A" name="Warfarin" oid="2.16.840.1.113883.3.117.1.7.1.232" suppDataElement="false" taxonomy="RxNorm" uuid="40280381-3e93-d1af-013e-9e3e039b08f0" version="1"/><qdm codeSystemName="National Committee for Quality Assurance" datatype="Laboratory Test, Result" id="40280381-3e93-d1af-013e-9e3e039b08f1" name="Computed Value INR percent TTR" oid="2.16.840.1.113883.3.464.1003.104.12.1018" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3e93-d1af-013e-9e3e039b08f1" version="1"/><qdm codeSystemName="National Committee for Quality Assurance" datatype="Medication, Active" id="40280381-3e93-d1af-013e-fb53b9f4456b" name="Dabigatran" oid="2.16.840.1.113883.3.464.1003.196.12.1258" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3e93-d1af-013e-fb53b9f4456b" version="1"/><qdm codeSystemName="National Committee for Quality Assurance" datatype="Medication, Active" id="40280381-3e93-d1af-013e-fb53b9f5456c" name="Rivaroxaban" oid="2.16.840.1.113883.3.464.1003.196.12.1259" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3e93-d1af-013e-fb53b9f5456c" version="1"/></elementLookUp><measureObservations displayName="Measure Observations"><clause displayName="Measure Observation 1" type="measureObservation" uuid="40280381-3e93-d1af-013e-9e3e45fe095f"><logicalOp displayName="AND" type="and"><functionalOp displayName="AVG" type="AVG" uuid="77dd5b1d-c0e3-4f77-8f50-aa1a03338109"><relationalOp displayName="During" type="DURING"><elementRef displayName="Computed Value INR percent TTR : Laboratory Test, Result" id="40280381-3e93-d1af-013e-9e3e039b08f1" type="qdm"/><elementRef displayName="Measurement Period : Timing Element" id="40280381-3e93-d1af-013e-9e3e039b08e7" type="qdm"/></relationalOp></functionalOp></logicalOp></clause></measureObservations><strata displayName="Stratification"><clause displayName="Stratum 1" type="stratum" uuid="40280381-3e93-d1af-013e-9e3e4d3a096c"><logicalOp displayName="AND" type="and"/></clause></strata></measure>
